XM tidak menyediakan perkhidmatan kepada penduduk Amerika Syarikat.

Dow advances to record high after inflation report; small caps outperform



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>US STOCKS-Dow advances to record high after inflation report; small caps outperform</title></head><body>

For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.

U.S. PCE stands at 2.2% in Aug

Russell 2000 index up 1.5%

Bristol-Myers gains after schizophrenia drug approval

Costco slips after Q4 revenue misses estimates

Indexes: Dow up 0.97%, S&P 500 up 0.05%, Nasdaq off 0.34%

Updated at 11:50 a.m. ET/1550 GMT

By Johann M Cherian and Purvi Agarwal

Sept 27 (Reuters) - The blue-chip Dow rose onFriday to hit an intraday recordand small-cap stocks outperformed after a benign inflation report cleared the way for the Federal Reserve to focus on shoring up the labor market while continuing its interest rate easing.

A Commerce Department's report showed that consumer spending increased moderately in August, suggesting the economy retained some of its solid momentum in the third quarter, while inflation pressures continued to abate.

At 11:50 a.m. ET, theDow Jones Industrial Average .DJI rose 410.80 points, or 0.97%, to 42,585.91, the S&P 500 .SPX gained 2.69 points, or 0.05%, to 5,748.00 and the Nasdaq Composite .IXIC lost 61.33 points, or 0.34%, to 18,128.96.

The Russell 2000 index .RUT, which tracks small caps that fare better in a low rate environment, gained 1.5% to a one-week high.

Ten out of the 11 S&P 500 sectors were higher, led by a 2% rise in energy stocks .SPNY, while technology stocks .SPLRCT declined 1%.

Nasdaq components such as Nvidia NVDA.O and Microsoft MSFT.O lost 2.7% and 0.5%, respectively, as investors turned their focus to other sectors.

Financial stocks including Goldman Sachs GS.N and healthcare stocks like UnitedHealth UNH.N were the biggest boosts to the Dow.

Investors now slightly favor a bigger 50 basis point cut at the Fed's next meeting with a 52.1% chance, up from a coin toss before the data, as per the CME Group's FedWatch Tool.

Cooling price pressuresgave the Fed enough room to commence its policy easing cycle with a 50 bps cutlast week. Focus will now shift to a slew of labor market reports due next week.

"Markets are just hopeful that we get more cuts. The Fed may accelerate this cutting cycle, but we may not get another 50 bps cut unless we get some bad data - a negative jobs report or a spike in unemployment," said John Luke Tyner, portfolio manager at Aptus Capital Advisors.

Meanwhile, the University of Michigan's final September estimate on consumer sentiment stood at 70.1, compared with estimates of 69.3, as per economists polled by Reuters.

Markets will parse through remarks from Fed Governor Michelle Bowman later in the day.

Late on Thursday, Fed Governor Lisa Cook said the central bank's rare move earlier this month could address increased "downside risks" to employment.

Wall Street's main indexes ended higher in the previous session, with the S&P 500 .SPX closing at a record high level. All three indexes are on track for theirthird straight week of gains.

Among other stocks, Bristol-MyersSquibb BMY.N surged 3.2% after the U.S. FDA approved its schizophrenia drug.

Costco Wholesale COST.O dropped 1.7% after postingdownbeat fourth-quarter revenue.

U.S.-listed shares of Chinese firms such as Alibaba BABA.N rose 2.8%, PDD Holdings PDD.O climbed 4.4% and NetEase NTES.O gained 3%after China's central bank lowered interest rates and injected liquidity into the banking system.

The optimism spilled over to minerssuch as Arcadium<ALTM.N>, which added 3.5%, and U.S.-listed shares of BHP BHP.N rose 1.8%.

Advancing issues outnumbered decliners by a 3.39-to-1 ratio on the NYSE and by a 2.37-to-1 ratio on the Nasdaq.

The S&P 500 posted 39 new 52-week highs and no new lows, while the Nasdaq Composite recorded 61 new highs and 48 new lows.


PCE, the shorter term view https://reut.rs/3WXgbkd


Reporting by Johann M Cherian and Purvi Agarwal in Bengaluru; Editing by Anil D'Silva and Maju Samuel

</body></html>

Penafian: Entiti XM Group menyediakan perkhidmatan pelaksanaan sahaja dan akses ke Kemudahan Dagangan Atas Talian, yang membolehkan sesorang melihat dan/atau menggunakan kandungan yang ada di dalam atau melalui laman web, tidak bertujuan untuk mengubah atau memperluas, juga tidak mengubah atau mengembangkannya. Akses dan penggunaan tersebut tertakluk kepada: (i) Terma dan Syarat; (ii) Amaran Risiko; dan Penafian Penuh. Oleh itu, kandungan sedemikian disediakan tidak lebih dari sekadar maklumat umum. Terutamanya, perlu diketahui bahawa kandungan Kemudahan Dagangan Atas Talian bukan permintaan, atau tawaran untuk melakukan transaksi dalam pasaran kewangan. Berdagang dalam mana-mana pasaran kewangan melibatkan tahap risiko yang besar terhadap modal anda.

Semua bahan yang diterbitkan di Kemudahan Dagangan Atas Talian kami bertujuan hanya untuk tujuan pendidikan/maklumat dan tidak mengandungi – dan tidak boleh dianggap mengandungi nasihat kewangan, cukai pelaburan atau dagangan dan cadangan, atau rekod harga dagangan kami, atau tawaran, atau permintaan untuk suatu transaksi dalam sebarang instrumen kewangan atau promosi kewangan yang tidak diminta kepada anda.

Sebarang kandungan pihak ketiga serta kandungan yang disediakan oleh XM, seperti pendapat, berita, penyelidikan, analisis, harga, maklumat lain atau pautan ke laman web pihak ketiga yang terdapat dalam laman web ini disediakan berdasarkan "seadanya" sebagai ulasan pasaran umum dan bukanlah nasihat pelaburan. Sesuai dengan apa-apa kandungan yang ditafsir sebagai penyelidikan pelaburan, anda mestilah ambil perhatian dan menerima bahawa kandungan tersebut tidak bertujuan dan tidak sediakan berdasarkan keperluan undang-undang yang direka untuk mempromosikan penyelidikan pelaburan bebas dan oleh itu, ia dianggap sebagai komunikasi pemasaran di bawah peraturan dan undang-undang yang berkaitan. SIla pastikan bahawa anda telah membaca dan memahami Notifikasi mengenai Penyelidikan Pelaburan Bukan Bebas dan Amaran Risiko mengenai maklumat di atas yang boleh diakses di sini.

Amaran Risiko: Modal anda dalam risiko. Produk yang berleveraj mungkin tidak sesuai untuk semua individu. Sila pertimbangkan Pendedahan Risiko kami.